Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32273660.
- Also identified by DOI 10.1016/j.jor.2020.03.028 and PMC identifier 7132050.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This investigation is a prospective cohort study examining the use of <i>Clostridium histolyticum</i> collagenase injection (CCH) for the treatment of Dupuytren's disease (DD) with a 7 years follow-up. Forty-five monodigital DD patients were injected with CCH on a single joint. Assessment included measurement of residual passive extension deficit (PED), function (using QuickDASH) and patient satisfaction. 86.7% of PIPJ and 65.6% of MPJ had a worsening of PED. Nevertheless, thirty-nine patients (86.7%) concluded their treatment with only one injection, without any further treatment. CCH provides a long-term effective solution. Recurrence occurs, especially in PIPJ, with acceptable rates.